CVKD Stock Analysis: Buy, Sell, or Hold?
CVKD - Cadrenal Therapeutics, Inc. Common Stock
$6.95
-0.51 (-6.84%)
▼
5d:
-4.27%
30d:
+4.98%
90d:
-45.96%
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When CVKD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CVKD this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CVKD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: CVKD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: CVKD is currently trading at $6.95, which is considered oversold relative to its 30-day fair value range of $7.00 to $8.07.
Technical Outlook: Technically, CVKD is in a strong downtrend. The price is currently testing key support at $6.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.67 (+413.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CVKD is in a strong downtrend. The price is currently testing key support at $6.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.67 (+413.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$7.00 -
$8.07
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 413.2% below Wall St target ($35.67)
Fair Price Analysis
30-Day Fair Range
$7.00 -
$8.07
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$6.85
Resistance Level
$8.29
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.39
Wall Street Target
$35.67
(+413.2%)
Last updated: February 01, 2026 10:59 PM ET
Data refreshes hourly during market hours. Next update: 11:59 PM
Data refreshes hourly during market hours. Next update: 11:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CVKD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
18
Sells
Net
INSIDERS SELLING
Recent Transactions
Quang X Pham
SELL
1800 shares
2025-10-13
Matthew K Szot
SELL
1800 shares
2025-10-13
Matthew K Szot
SELL
1693 shares
2025-10-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$477 | 45 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$277 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$19 | 55 HOLD |
